AKT1 and cancer: These concentrations were chosen based on the IC50 values of the compounds (19.3 μM for alpelisib, 1.75 μM for trametinib, and 85.1 μM for SB203580) [41,42,43], their inhibitory effect on overall Akt and ERK levels, and their effect on cancer cell chemotaxis.